Myostatin inhibitors are being explored as a way to counteract muscle loss from GLP-1 weight loss drugs while also treating metabolic disorders directly.
Muscle loss is the top long-term concern with GLP-1 therapyGLP-1 analogs suppress appetite so effectively that reduced nutritional intake leads to significant muscle loss, prompting the search for combination approaches using myostatin inhibitors.
What the researchers found
GLP-1 analogs cause significant muscle loss as a side effect of appetite suppression and reduced nutritional intake, creating a clinical problem for long-term weight management. Myostatin (MSTN) inhibitors — which dramatically increase muscle mass — are emerging as a potential solution, both to counteract GLP-1-associated sarcopenia and as standalone treatments for metabolic disorders including obesity and diabetes. Clinical trials are now investigating MSTN inhibitors alone and in combination with GLP-1 analogs.
Why it matters
Millions of people now take GLP-1 drugs like semaglutide and tirzepatide for weight loss, but muscle loss is becoming one of the most concerning side effects. This review highlights myostatin inhibitors as a promising class of drugs that could preserve or build muscle while patients continue losing fat — potentially solving one of the biggest problems with current obesity medications.
How the study worked
This is a narrative review that examines the therapeutic potential of myostatin inhibitors, summarizing current research and clinical trials investigating their use alone or combined with GLP-1 analogs for metabolic disorders.
Who was studied
Review covering patients on GLP-1 therapy experiencing muscle loss, and broader metabolic disorder populations
What this study cannot tell us
As a review article, this does not present new experimental data. Many of the clinical trials discussed for myostatin inhibitors in metabolic contexts are still ongoing, so definitive efficacy and safety conclusions cannot yet be drawn. The review focuses on the theoretical rationale for combination therapy, which remains largely unproven in large-scale human trials.
How to read the evidence
This is a review article that synthesizes existing research and ongoing clinical trials. It does not present original experimental data, so conclusions about myostatin inhibitor efficacy in this context are preliminary and await results from ongoing trials.
When this study was published
Published in 2025, this is a very current review that reflects the latest developments in both GLP-1 therapy side effect management and myostatin inhibitor research.
The bigger picture
The explosive growth of GLP-1 drugs has created a new clinical challenge: how to prevent the loss of lean muscle mass that accompanies rapid weight loss. This review positions myostatin inhibitors as the leading pharmaceutical answer, reflecting a broader shift toward combination therapies that target both fat loss and muscle preservation simultaneously — what some are calling the next frontier in obesity treatment.
Questions still open
- How effective are myostatin inhibitors at preserving muscle mass when combined with GLP-1 drugs in large human trials?
- Could myostatin inhibitors themselves become standalone obesity treatments by increasing metabolically active muscle tissue?
- What are the long-term safety profiles of combining two powerful peptide-based drug classes?
Common questions
Why do GLP-1 drugs cause muscle loss?
What are myostatin inhibitors and how could they help?
Read the original research
Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.
Journal of bone metabolism, 32(4), 263-275
Citation
Baik, Jongmin; Lee, Yun-Sil. (2025). Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.. Journal of bone metabolism, 32(4), 263-275. https://doi.org/10.11005/jbm.25.919